A piece of American manufacturing history just got a financial boost. Cherokee Brick, a company founded in 1877 and continuously family-owned since 1900, has raised $100K in new capital. The brick maker stands out as one of the few American and family-owned companies in its industry, supplying a wide array of brick sizes and colors across 32 states. From classic collections to specialized thin brick and custom shapes, Cherokee Brick offers extensive options for builders.
Cherokee Brick Raises $100K
Get the full Cherokee Brick company profile
Access contacts, investors, buying signals & more
From the source
vc_portfolio_runner · May 12, 2026Portfolio company of Third Wave Digital
Other United States companies recently funded
View all
Euka AI
Top e-commerce brands use Euka to drive TikTok Shop sales. Produce winning content in partnership with trending creators, then multiply content with our suite of AI content generation tools.
$5.0M Seed
today
Retham Technologies
Retham Technologies™ LLC was established in 2017 to translate recent discoveries into a life-saving in vitro diagnostic (IVD) assay that provides earlier and more accurate in-hospital diagnosis of Heparin-induced Thrombocytopenia (HIT). ​ HIT is a serious adverse reaction to the blood thinner heparin. It is characterized by a drop in platelet count (thrombocytopenia) and in ~1/3rd of cases, causes blood clotting (thrombosis) that can result in life-and-limb threatening consequences such as amputation, stroke and death. The diagnosis of HIT is challenging. A family of easy-to-run tests called PF4 ELISAs is performed in the hospital laboratory but have high false positive rates, i.e. many patients positive for antibodies to PF4:polyanion complexes do not have clinical HIT. A second test, the Serotonin release assay (SRA), is considered the “gold-standard” test for HIT; but, it is performed only at a handful of laboratories nationally on a small fraction of suspected cases due to technical complexity, cost and turnaround time concerns. Thus, >90% of HIT suspected patients are currently managed using PF4 ELISAs, and thousands of patients receive costly non-heparin anticoagulant therapy due to “false positive” diagnoses. These alternative anticoagulants have a worse bleeding risk profile relative to heparin often resulting in severe or fatal hemorrhage. Retham Technologies™ is developing HITDx™, an IVD assay for early and accurate near-patient HIT diagnosis that is expected to facilitate timely and appropriate therapy thereby leading to better outcomes.
Biggest recent Manufacturing rounds
Largest funding rounds in Manufacturing on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Vale Brazil | Unknown | $18.0B | 2y ago |
| 2 |  Tower Semiconductor Israel | Unknown | $10.0B |
Other recent Unknown rounds
Companies that recently closed a Unknown round.
